HopeStage
Back to all studies
CompletedNCT03164876

AUT00206 Added to Care for Schizophrenia: Safety and Brain Measures

About this titleRead the official source — NCT03164876

This study evaluated the safety of AUT00206 for people with schizophrenia.

Medication studyAges 18–50United Kingdom
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety of AUT00206 for people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Listed locations
LondonSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: April 20, 2017
Recruitment status
Completed
Enrollment listed in the registry
24
Sponsor
Autifony Therapeutics Limited
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United Kingdom
Age range
From 18 Years to 50 Years
Official registry ID
NCT03164876
Official title
Show the full official title

A Randomised, Double-blind, Placebo-controlled Study of the Safety, Pharmacokinetics and Exploratory Pharmacodynamics of AUT00206 for 28 Days as Adjunctive Therapy in Patients With Recently Diagnosed Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

London

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety of AUT00206 for people with schizophrenia.

Who is behind this study?

The study sponsor is Autifony Therapeutics Limited.

Did this study involve medication?

Yes. The study involved medication, including AUT00206 and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies